$BIOVF News
Last published 1w ago
- 1w agoSOBIsBIOVFBörje Ekholm is proposed as new Chair of the Sobi Board of DirectorsPR NewswireThe Nomination Committee of Swedish Orphan Biovitrum AB (Sobi®) proposes that Börje Ekholm is elected as new Board member and Chair of the Board at the 2027 Annual General Meeting (AGM).STOCKHOLM, Oct. 29, 2026
- 3y agoBIOVFPositive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum ABPR NewswirePrimary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile of efanesoctocog alfa in previously treated patients under 12 years of ageThe completion of XTEND-Kids represents the final
- 3y agoBIOVFSobi publishes Q4 and FY 2022 report: a good year and a solid futurePR NewswireSTOCKHOLM, Feb. 8, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2022 Fourth quarter 2022 Total revenue SEK 5,991 M (4,896), +22
- 3y agoBIOVFChanges to Sobi's managementPR NewswireTony Hoos to replace Anders Ullman as Head of R&D and Medical Affairs and Chief Medical Officer from 1 April 2023. STOCKHOM, Feb. 2, 2023 /PRNewswire/ -- Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of
- 3y agoBIOVFBo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (publ) ahead of the Annual General Meeting in 2023PR NewswireSTOCKHOLM, Nov. 18, 2022 /PRNewswire/ -- As previously communicated, Håkan Björklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB (publ) (Sobi®), has announced that he will not be available for
- 4y agoBIOVFSobi to present new data at the ASH 2022 Annual MeetingPR NewswireSTOCKHOLM, Nov. 11, 2022 /PRNewswire/ -- Sobi® will present new data at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place from 10 to 13 December 2022. Sobi's commitment to
- 4y agoBIOVFSwedish Orphan Biovitrum AB (publ)'s Chairman of the Board Håkan Björklund will not be available for re-election at the Annual General Meeting 2023PR NewswireSTOCKHOLM, Oct. 31, 2022 /PRNewswire/ -- Håkan Björklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB (publ) (Sobi®), has today notified the Nomination Committee that he is not available for
- 4y agoBIOVFSobi publishes Q3 2022 reportPR NewswireSTOCKHOLM, Oct. 27, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter of 2022 July - September 2022 Total revenue SEK 3,999 M (3,761), +6 per
- 4y agoBIOVFNew number of shares and votes in Swedish Orphan Biovitrum AB (publ)PR NewswireSTOCKHOLM, Sept. 30, 2022 /PRNewswire/ -- As per 30 September 2022, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 309,804,782 shares. All shares are common shares. The total number of votes is 309,804,782. The incre
- 4y agoADCTBIOVFSobi to license loncastuximab tesirine from ADC TherapeuticsPR NewswireAgreement augments Sobi's strategic presence in haematology with new orphan medicine STOCKHOLM, July 8, 2022 /PRNewswire/ -- Sobi® today announced an exclusive license agreement with ADC Therapeutics SA to develop and commercialise loncastuximab tesi
- 4y agoBIOVFSobi publishes Q1 2022 reportPR NewswireSTOCKHOLM, April 28, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2022 January – March 2022 Total revenue SEK 4,925 M (3,661), +35 per cent, +24 per cent at constant
- 4y agoBIOVFSobi publishes 2021 Annual and Sustainability ReportPR NewswireSTOCKHOLM, April 5, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) has released the company's 2021 Annual and Sustainability Report. The integrated report summarises business and strategy, financial performance and work on sustainabil
- 4y agoBIOVFSobi to cease ReFacto manufacturing in the first quarter of 2024PR NewswireSTOCKHOLM, March 23, 2022 /PRNewswire/ -- Sobi® today announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® (ReFacto) has been amended due to clarity of final order volumes and will now expire in the fir
- 4y agoBIOVFSNYEfanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatmentPR NewswireOnce-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of b
- 4y agoBIOVFGamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)PR NewswireSTOCKHOLM, Feb. 25, 2022 /PRNewswire/ -- Sobi® today announces that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant® to the National Medical Products Administration of China (NMPA). The indication is for treatment of adult and
- 4y agoBIOVFSobi publishes Q4 and FY 2021 reportPR NewswireSTOCKHOLM, Feb. 10, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces its results for the fourth quarter and full year of 2021. Link to report below. Investors, analysts and media are invited to participate in a confe
- 4y agoBIOVFInvitation: Sobi's Q4 and FY 2021 reportPR NewswireSTOCKHOLM, Feb. 3, 2022 /PRNewswire/ -- Sobi plans to publish its report for the fourth quarter and full-year 2021 on 10 February 2022 at 08:00 CET. Investors, analysts and media are invited to participate in a conference call, which will include a pre
- 4y agoBIOVFSobi to present new data at EAHAD 2022PR NewswireSTOCKHOLM, Feb. 2, 2022 /PRNewswire/ -- Sobi™ will present new data at the 15th European Association of Haemophilia and Allied Disorders (EAHAD) virtual conference from 2-4 February 2022, contributing to the safety and efficacy profile and long-term b
- 4y agoBIOVFKineret® (anakinra) receives positive opinion from the CHMP for treatment of patients with COVID-19 pneumoniaPR NewswireSTOCKHOLM, Dec. 16, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of Kine
- 4y agoAPLSBIOVFAspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNHPR NewswireSTOCKHOLM, Dec. 15, 2021 /PRNewswire/ -- The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels1 Aspa
- 4y agoBIOVFSobi continues the R&D transformation - Anders Ullman appointed new Head of R&DPR NewswireSTOCKHOLM, Dec. 13, 2021 /PRNewswire/ -- Anders Ullman, M.D., Ph.D., currently a member of the Board of Directors of Sobi, will become Head of R&D and Chief Medical Officer and replace Ravi Rao, M.D., Ph.D. Dr Ullman brings extensive experience and knowl
- 4y agoBIOVFStatement by the Board of Directors in relation to the withdrawal of the public cash offer by Advent and GICPR NewswireSTOCKHOLM, Dec. 3, 2021 /PRNewswire/ -- The Board of Directors remains fully committed to Sobi and Sobi's strategy Håkan Björklund, Chairman of the Board of Directors: "We are as committed as ever to helping people with rare diseases. The Board an
- 4y agoBIOVFSELBSobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory goutPR NewswireSTOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ:SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DIS
- 5y agoBIOVFSobi to present new data at the ASH 2021 Annual MeetingPR NewswireSTOCKHOLM, Nov. 4, 2021 /PRNewswire/ -- Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021. Sobi's commitment to developing innovative treatments for people living wi
- 5y agoAPLSBIOVFAspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNHPR NewswireSTOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announce today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agenc
- 5y agoBIOVFInvitation - Presentation of Sobi's Q2 2021 resultsPR NewswireSTOCKHOLM, July 8, 2021 /PRNewswire/ -- On 21 July, at 08:00 CEST, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2021. Investors, financial analysts and media are invited to participate in a telephone confere
- 5y agoBIOVFSobi to present data at the ISTH 2021 within rare haematology diseasesPR NewswireSTOCKHOLM, July 7, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) presents data at the virtual ISTH 2021, the 29th Congress of the International Society on Thrombosis and Haemostasis, 17 – 21 July 2021. Nine abstracts featuring four
- 5y agoBIOVFSobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITPPR NewswireSTOCKHOLM, June 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) will present data at the EHA (European Haematology Association) virtual congress, 9-17 June 2021, highlighting the company's advancement of treatments for rare haematolo
- 5y agoAPLSBIOVFPositive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNHPR NewswireSTOCKHOLM, May 25, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) and Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) (GLOBE NEWSWIRE) today reported positive top-line results from the phase 3 PRINCE study evaluating the efficacy and safet
- 5y agoBIOVFSwedish Orphan Biovitrum AB to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 4, 2021 / Swedish Orphan Biovitrum AB (STO:SOBI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 1:00 PM Eastern Time. To listen to the event live or access
- 5y agoBIOVFInvitation - Presentation of Sobi's Q1 2021 resultsPR NewswireSTOCKHOLM, April 26, 2021 /PRNewswire/ -- On 4 May, at 08:00 CEST, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the first quarter 2021. Investors, financial analysts and media are invited to participate in a telephone conferen